Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Casein kinase 2 (CK2) is a highly active protein kinase overexpressed in cancer cells, contributing to tumorigenesis.
• Targeting CK2 is a promising strategy for cancer treatment.

Purpose of the Study:

• To design and synthesize novel Proteolysis Targeting Chimeras (PROTACs) for the degradation of CK2 protein.
• To evaluate the efficacy of these PROTACs in degrading CK2 and their impact on cancer-related signaling pathways.

Main Methods:

• Synthesis of PROTACs by conjugating a CK2 inhibitor (CX-4945) with pomalidomide using "click reaction".
• Assessment of compound 2's ability to degrade CK2 in a dose- and time-dependent manner.
• Analysis of downstream effects, including Akt phosphorylation and p53 levels.

Main Results:

• Compound 2 demonstrated effective degradation of CK2 protein via the ubiquitin-proteasome system.
• CK2 degradation led to decreased Akt phosphorylation and increased p53 levels.
• Compound 2 exhibited cytotoxicity similar to the CK2 inhibitor CX-4945, but through a distinct mechanism.

Conclusions:

• PROTAC-mediated degradation of CK2 is a viable therapeutic strategy for cancer treatment.
• Compound 2 represents a potential novel cancer therapeutic agent by degrading CK2.
• This approach offers a different mechanism of action compared to traditional CK2 inhibitors.